Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 29, 2022 07:35 ET | Source: Reneo Pharmaceuticals, Inc.

Reneo Pharmaceuticals Announces Poster Presentations at the International Network for Fatty Acid Oxidation Research and Management Annual Meeting

IRVINE, Calif., Aug. 29, 2022 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (Nasdaq: RPHM), a clinical stage pharmaceutical company focused on the development and commercialization of therapies...
August 09, 2022 08:00 ET | Source: Reneo Pharmaceuticals, Inc.

Reneo Pharmaceuticals Reports Second Quarter 2022 Financial Results

IRVINE, Calif., Aug. 09, 2022 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (Nasdaq: RPHM), a clinical-stage pharmaceutical company focused on the development and commercialization of therapies...
August 02, 2022 07:30 ET | Source: Reneo Pharmaceuticals, Inc.

Reneo Pharmaceuticals Appoints Roshawn Blunt to its Board of Directors

IRVINE, Calif., Aug. 02, 2022 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (Nasdaq: RPHM), a clinical stage pharmaceutical company focused on the development and commercialization of therapies...
July 26, 2022 07:30 ET | Source: Reneo Pharmaceuticals, Inc.

Reneo Pharmaceuticals Reports Positive Results from REN001 Long-Chain Fatty Acid Oxidation Disorders (LC-FAOD) Study and Provides Additional Development Updates

LC-FAOD program to move forward into the next stage of clinical developmentEnrollment of pivotal STRIDE study in primary mitochondrial myopathies (PMM) patients with mitochondrial DNA (mtDNA) defects...
July 11, 2022 08:00 ET | Source: Reneo Pharmaceuticals, Inc.

Reneo Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

IRVINE, Calif., July 11, 2022 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (Nasdaq: RPHM), a clinical stage pharmaceutical company focused on the development and commercialization of therapies...
June 30, 2022 08:00 ET | Source: Reneo Pharmaceuticals, Inc.

Reneo Pharmaceuticals to Present Data from Phase 1 REN001 Limb Immobilization Study at the 17th International Congress on Neuromuscular Diseases (ICNMD 2022)

IRVINE, Calif., June 30, 2022 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (Nasdaq: RPHM), a clinical stage pharmaceutical company focused on the development and commercialization of therapies...
May 10, 2022 16:05 ET | Source: Reneo Pharmaceuticals, Inc.

Reneo Pharmaceuticals Reports First Quarter 2022 Financial Results

IRVINE, Calif., May 10, 2022 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (Nasdaq: RPHM), a clinical stage pharmaceutical company focused on the development and commercialization of therapies for...
March 23, 2022 16:05 ET | Source: Reneo Pharmaceuticals, Inc.

Reneo Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update

IRVINE, Calif., March 23, 2022 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (Nasdaq: RPHM), a clinical stage pharmaceutical company focused on the development and commercialization of therapies...
March 07, 2022 08:30 ET | Source: Reneo Pharmaceuticals, Inc.

Reneo Pharmaceuticals Announces Senior Leadership Promotions

Michael P. Cruse appointed Chief Operating OfficerJennifer P. Lam appointed Principal Financial and Accounting Officer IRVINE, Calif., March 07, 2022 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals,...
February 02, 2022 08:00 ET | Source: Reneo Pharmaceuticals, Inc.

Reneo Pharmaceuticals to Participate in SVB Leerink Virtual Global Healthcare Conference

IRVINE, Calif., Feb. 02, 2022 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (NASDAQ: RPHM), a clinical stage pharmaceutical company focused on the development and commercialization of therapies...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right